Evidence for DNA methylation mediating genetic liability to non-syndromic cleft lip/palate by Howe, Laurence et al.
                          Howe, L., Richardson, T., Arathimos, R., Alvizi, L., Passos-Bueno, M. R.,
Stanier, P., ... Sharp, G. (2019). Evidence for DNA methylation mediating
genetic liability to non-syndromic cleft lip/palate. Epigenomics, 11(2), 133-
145. https://doi.org/10.2217/epi-2018-0091
Publisher's PDF, also known as Version of record
License (if available):
CC BY
Link to published version (if available):
10.2217/epi-2018-0091
Link to publication record in Explore Bristol Research
PDF-document
This is the final published version of the article (version of record). It first appeared online via [insert publisher
name] at [insert hyperlink] . Please refer to any applicable terms of use of the publisher.
University of Bristol - Explore Bristol Research
General rights
This document is made available in accordance with publisher policies. Please cite only the published
version using the reference above. Full terms of use are available:
http://www.bristol.ac.uk/pure/about/ebr-terms
Research Article
For reprint orders, please contact: reprints@futuremedicine.com
Evidence for DNA methylation mediating
genetic liability to non-syndromic cleft
lip/palate
Laurence J Howe1,2, Tom G Richardson1, Ryan Arathimos1, Lucas Alvizi3, Maria R
Passos-Bueno, Philip Stanier4, Ellen Nohr5, Kerstin U Ludwig6,7, Elisabeth Mangold6,
Michael Knapp8, Evie Stergiakouli1, Beate St Pourcain1,9,10, George Davey Smith1, Jonathan
Sandy11, Caroline L Relton1, Sarah J Lewis1,11, Gibran Hemani1 & Gemma C Sharp*,1,11
1MRC Integrative Epidemiology Unit, Population Health Sciences, University of Bristol, BS8 2BN, UK
2Institute of Cardiovascular Science, University College London, London, NW1 2DA, UK
3Centro de Pesquisas Sobre o Genoma Humano eCe´lulas-Tronco, Instituto de Biocieˆncias, Universidade de Sa˜o Paulo, Sa˜o Paulo,
Brazil
4Genetics & Genomic Medicine, UCL Great Ormond Street Institute of Child Health, University College London, London, WC1N
3JH, UK
5Institute of Public Health, Aarhus University, Aarhus, Denmark
6Institute of Human Genetics, University of Bonn, 53127 Bonn, Germany
7Department of Genomics, Life & Brain Center, University of Bonn, 53127 Bonn, Germany
8Institute of Medical Biometry, Informatics & Epidemiology, University of Bonn, 53127 Bonn, Germany
9Max Planck Institute for Psycholinguistics, Nijmegen, 6525 XD, Netherlands
10Donders Institute, 6525 EN Nijmegen, The Netherlands
11Bristol Dental School, University of Bristol, BS8 2BN, UK
*Author for correspondence: gemma.sharp@bristol.ac.uk
Aim: To determine if nonsyndromic cleft lip with or without cleft palate (nsCL/P) genetic risk variants
influence liability to nsCL/P through gene regulation pathways, such as those involving DNA methyla-
tion. Materials & methods: nsCL/P genetic summary data and methylation data from four studies were
used in conjunction with Mendelian randomization and joint likelihood mapping to investigate poten-
tial mediation of nsCL/P genetic variants. Results & conclusion: Evidence was found at VAX1 (10q25.3),
LOC146880 (17q23.3) and NTN1 (17p13.1), that liability to nsCL/P and variation in DNAmethylation might
be driven by the same genetic variant, suggesting that genetic variation at these loci may increase liability
to nsCL/P by influencing DNAmethylation. Follow-up analyses using different tissues and gene expression
data provided further insight into possible biological mechanisms.
First draft submitted: 21 June 2018; Accepted for publication: 18 September 2018; Published online:
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Orofacial clefts are a heterogeneous group of congenital malformations [1]. In epidemiology and genetics research,
orofacial clefts are often divided into the subtypes cleft palate only (CPO) and cleft lip with or without cleft
palate (CL/P), with strong evidence for distinct etiologies [1]. There is also accumulating evidence suggesting that
the CL/P subtypes cleft lip only (CLO) and cleft lip with cleft palate (CLP) may also differ etiologically [2,3].
Mendelian syndromes can feature CL/P and CPO but around 70% of CL/P cases are non-syndromic (nsCL/P),
with a complex etiology likely to involve genetic and environmental risk factors [4,5], in addition to stochastic events
which are not driven by germline genetic or environmental exposures as these are commonly understood [6].
Genome-wide association studies (GWAS) have identified around 40 distinct genetic risk variants for nsCL/P
in European and Asian populations [2,7–14], but many variants reside in non-protein coding regions and so their
functional relevance remains unclear. One possibility is that genetic risk variants may be affecting nsCL/P suscep-
tibility through gene regulation pathways. Indeed, a noncoding interval at 8q24, a major nsCL/P risk locus, has
previously been shown to regulate gene expression in the developing murine face, suggesting similar mechanisms
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Figure 1. Possible explanations for an association between methylation quantitative trait loci and nonsyndromic cleft lip with or
without cleft palate. These include (A) mediation, (B) reverse causation, (C) linkage and (D) horizontal pleiotropy. In this study, we
attempted to identify loci where genetic influences on nonsyndromic cleft lip with or without cleft palate are mediated by DNA
methylation, i.e. (A).
nsCL/P: Nonsyndromic cleft lip with or without palate; SNP: Single nucleotide polymorphism.
in humans [15]. There is increasing evidence that epigenetic mechanisms, such as DNA methylation, play a role in
development of orofacial clefts [16–19], potentially via changes to gene expression.
In this study, we applied a recently devised analysis framework [20,21] to explore whether genetic influences
on liability to nsCL/P are mediated by DNA methylation, using DNA methylation assayed in whole blood as a
proxy for DNA methylation in more relevant tissues. Genetic variants that are associated with DNA methylation
(methylation quantitative trait loci; mQTL) have been previously identified in the Avon Longitudinal Study of
Parents and Children (ALSPAC) [22]. We used these mQTL to perform Mendelian randomization (MR), an
epidemiological tool typically used to explore causal relationships between modifiable risk factors and health or
disease outcomes [23]. In this instance, genetic variants robustly associated with DNA methylation were tested
for association with nsCL/P. We considered four possible models to explain an association between a mQTL
and nsCL/P: DNA methylation mediates the effect of a genetic variant on liability to nsCL/P; the direction
of effect is reversed, in other words, an individual’s overall genetic liability to nsCL/P causes variation in DNA
methylation; DNA methylation and liability to nsCL/P are influenced by separate genetic variants that are in
linkage disequilibrium (LD) with each other; DNA methylation and liability to nsCL/P are influenced by the
same genetic variant, but via independent pathways, in other words, the association is due to horizontal pleiotropy
(Figure 1) [20,21].
We systematically applied additional analyses, including bidirectionalMR and colocalization, to estimate themost
likely model as far as possible, although we were unable to use recently derived MR methods [24,25] to distinguish
between mediation and horizontal pleiotropy because most CpGs are instrumented by a single genetic variant.
Where there was evidence that genetic influences on liability to nsCL/P may be mediated by DNAmethylation, we
explored associations with gene expression. We also compared our findings relating to genetic liability to nsCL/P in
the general population to results from an epigenome-wide association study (EWAS) of whole blood samples from
nsCL/P cases and unaffected controls. Given accumulating evidence that different subtypes of orofacial clefts have
distinct etiologies, we also explored whether identified CpGs are differentially methylated in blood samples from
children with different orofacial cleft subtypes. Finally, since the majority of our analyses used DNA methylation
derived in blood, which might not be representative of the developing orofacial tissues, as described previously [16],
we explored correlations between DNA methylation in blood and lip/palate tissue in the same individuals, under
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the (potentially false) assumption that methylation signatures in these tissues might reflect those of the developing
orofacial tissues more accurately.
Methods
Data sources
nsCL/P genetic risk variants
We identified single nucleotide polymorphisms (SNPs) associated with nsCL/P in European populations by
conducting a meta-analysis of summary statistics from two nsCL/P GWAS. Summary statistics for the first
GWAS came from a case–control study of 399 cases and 1,318 controls of central European descent [8]. For the
second GWAS, we generated summary statistics by conducting a GWAS using individual level data from 638
parent-offspring trios and 178 parent-offspring duos of European descent from the International Consortium to
Identify Genes and Interactions Controlling Oral Clefts (ICC). These data were available to download from dbGaP
(Study accession phs000094.v1.p1) [26]. Full GWAS methods are described in the Supplementary Material, but
briefly, we performed a transmission disequilibrium test [27] on the pedigree data. We then performed a fixed-
effects inverse-variance-weighted meta-analysis of the summary statistics from both GWAS using METAL [28] on
the total sample of 1215 cases and 2772 controls. The results compared well with those previously published
using a very similar dataset but slightly different quality control and analysis methods [7]. We used LiftOver
(genome.sph.umich.edu/wiki/LiftOver) to convert the genome positions in the nsCL/P summary statistics to the
most recent genome build 37. Finally, we used PLINK [29] and data from the ALSPAC as a reference panel to clump
the results according to LD (r2 < 0.001), within a 250 kb region around each index variant, and generate a set of
independent SNPs for the pipeline.
Methylation genetic risk variants (mQTL)
ALSPAC
To identify mQTL (SNPs associated with DNA methylation), we used data from ALSPAC [30,31]. In addition to
collecting detailed questionnaire and clinic data for the whole cohort, the study has generated genome-wide DNA
methylation and genotype data for subsets of the cohort [32] (methods described in the Supplementary Material).
These data have previously been used to generate a database of mQTL [22]. The database contains summary statistics
for all mQTL with a p-value < 1 × 10-7 for the association between SNP and CpG. For the purposes of this study,
we focused on the mQTL identified in cord blood samples collected at birth (the closest available time point to the
orofacial developmental period). For part of our study (the reverse two sampleMR), we required specific CpG–SNP
associations that were unavailable from mQTLdb.org. Therefore, for required CpGs, we replicated the methods
in the original study: we excluded individuals with missing genotype or covariate data, leaving 787 children. We
then rank-normalized the methylation data to remove outliers and controlled for covariates, potential batch effects
and the influence of cell heterogeneity by regressing data points on sex, the first 10 ancestry principal components,
bisulfite-converted DNA batch and blood cell proportions estimated using the Houseman method [33,34]. We then
calculated residuals, which were used as the outcome variable in a linear regression model in PLINK [29] to calculate
the relevant CpG–SNP associations.
Finally, we excluded any mQTL acting in trans (i.e., any SNP associated with a CpG site more than 1 M
base pairs away) and excluded any CpGs that have been flagged as potentially problematic (e.g., cross-hybridizing
probes) according to a previous publication [35].
GOYA
We attempted to replicate mQTL from ALSPAC using genotype and cord blood DNA methylation data from the
Genetics of Overweight Young Adults (GOYA) cohort, which is a subset of the Danish National Birth Cohort
(DNBC) [36]. Genotype and cord blood DNAmethylation data were available for 1000 children. We replicated the
methods described above for ALSPAC by first excluding individuals with missing genotype or covariate data, leaving
889 children and also removing SNPs with missingness (>5%) using PLINK. As in ALSPAC, we rank-normalised
the methylation data to remove outliers and adjusted for covariates, potential batch effects and the influence of cell
heterogeneity by regressing data points on sex, the first ten ancestry principal components, DNA batch and blood
cell proportions estimated using the Houseman method [33,34]. Residuals were then used as the outcome variable
in a linear regression model in PLINK to calculate the relevant CpG–SNP associations.
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Expression quantitative trait loci as genetic risk variants
Genotype-Tissue Expression project
To identify expression quantitative trait loci (eQTL; SNPs associated with gene expression), we used the Genotype-
Tissue Expression project (GTex) data, which is a database of eQTL generated using genotype and RNA sequencing
gene expression data for 43 distinct tissue types from 175 individuals [37,38].
NESDA NTR conditional eQTL catalog
To explore the consistency of our findings, we also identified eQTL using a second database: the NESDA NTR
Conditional eQTLCatalog. For this database, eQTLwere identified using genotype and gene expressionmicroarray
data from blood samples from 4896 individuals across twoDutch biobanks. Conditional eQTL analysis was applied
to distinguish between dependent and independent eQTL [39].
DNA methylation in children with orofacial clefts
Brazilian cohort
If genetic liability to nsCL/P is associated with DNA methylation at certain CpGs, we would expect these CpGs
to be differentially methylated between nsCL/P cases and controls. To assess whether this was the case at nsCL/P-
associated CpGs (identified throughMR), we performed a look-up of results from a recently-published case-control
EWAS [16]. This EWAS compared blood DNA methylation profiles in 67 nonfamilial, nsCL/P cases and 59 age-
and sex-matched controls from a Brazilian population. The average age at sampling was 5.29 years for cases and
6.45 years for controls. DNA methylation was measured using the Illumina Infinium HumanMethylation450
BeadChip platform.
The Cleft Collective
To explorewhethermethylation at nsCL/P-associatedCpGs differs by cleft subtype, we comparedmeanmethylation
values in blood andmatched lip/palate tissue samples from150 children from theUK enrolled in theCleft Collective
birth cohort study. Methylation data were generated for a separate study, as previously described[3]. Briefly, a sample
of 150 believed to be nonsyndromic children was randomly selected and stratified by cleft subtype: 50 with CLO,
50 with CPO and 50 with CLP. These children have been classified as nonsyndromic because they have not been
diagnosed as having any other anomaly, however, since the children are still very young, we cannot be completely
sure of their nonsyndromic status. Blood and either lip or palate tissue samples were available for each of the
150 children in this study. The orofacial tissue type was dependent on the orofacial cleft subtype; therefore, lip
samples were available for children with CLO and palate samples for children with CPO. Of the 50 children with
CLP, 43 contributed a lip sample and seven contributed a palate sample. Genome-wide DNA methylation was
measured using the Illumina Infinium HumanMethylation450 BeadChip platform and functional normalization
was performed on the blood and tissue samples together. Of the original 300 samples, three blood and two lip
samples failed quality control. Surrogate variables were generated using the sva package in R to capture variation in
the methylation data associated with technical batch and cellular heterogeneity [40].
Analysis pipeline
Testing for mediation: MR of the effect of methylation on liability to nsCL/P
nsCL/P meta-GWAS summary statistics for 543,150 SNPs were LD-pruned (r2 < 0.001) to 17,090 independent
SNPs. These independent SNPs were then merged with 127,215 mQTL from the ALSPAC mQTL database. After
removing potentially problematic CpGs and CpGs acting in trans (which may increase the likelihood of horizontal
pleiotropy), there were 7091 independent CpG–SNP pairings for 6425 distinct CpGs. We then used the MR-base
R package [41] to perform two-sample MR on all CpGs, using mQTL as the exposure variables and nsCL/P as the
outcome. In initial analysis, CpGs with one mQTL were tested using the Wald test and CpGs with more than
one mQTL were tested using the Inverse variance weighted (IVW) method. To account for possible residual LD
between mQTL, CpGs with more than one mQTL, were retested adjusting for LD between the SNPs using a
likelihood-based method [42]. Pair-wise SNP LD was computed using the Caucasian European (CEU) and British
(GBR) populations in LDlink [43]. As a sensitivity analysis, we attempted to replicate the SNP-CpG associations
with a Bonferroni-correctedMR p-value< 0.05 in GOYA, an independent sample, to further evaluate the evidence
that the SNP-CpG associations of interest are genuine.
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Testing for reverse causation: MR of the effect of genetic liability to nsCL/P on methylation
The MR analysis of methylation on nsCL/P used a single genetic instrument for the majority of CpGs, so it is
difficult to discern the direction of effect. Therefore, we used MR-base to conduct the reverse two-sample MR
to assess possibility B), reverse causation, that liability to nsCL/P causes downstream effects in methylation. Six
genome-wide significant nsCL/P SNPs in Europeans [7] were used as the exposure and mQTL from ALSPAC were
used as the outcome. The IVW method was used as the primary analysis.
Testing for linkage: joint-likelihood mapping to assess colocalization
We used the Joint likelihood mapping (JLIM) package in R ([jlim.R] [44] to test possibility C), liability to nsCL/P
and methylation are driven by the same causal effect in each region of interest, in other words, the mQTL and
nsCL/P risk variant are colocalized rather than simply being in LD. To distinguish between separate causal variants,
we set the limit of genetic resolution in terms of r2 to 0.8. 1000 Genomes [45] CEU data were used as the reference
dataset for LD. Most CpGs were associated with only one independent mQTL, so we were not able to distinguish
mediation/vertical pleiotropy (Figure 1A) from horizontal pleiotropy (Figure 1D).
Comparison to gene expression
The previous steps identified CpGs that potentially mediate the effect of genetic variation on susceptibility to
nsCL/P. Further evidence for a functional effect would be provided if mQTL also affected gene expression.
Therefore, we looked up relevant SNPs in two eQTL databases (GTEx [38] and NESDA NTR Conditional eQTL
Catalog [39]) and noted the estimated effect size and p-values for eQTL in various tissues.
Comparison to EWAS results
At identified CpGs, we looked-up the mean methylation values in nsCL/P cases and controls from the Brazilian
EWAS study to determine if CpGs of interest from theMRwere differentiallymethylated between nsCL/P cases and
controls. Evidence for differential methylation would further support an etiological role in nsCL/P. We compared
the direction of estimated effect and p-values obtained using the observational EWAS and MR approaches.
Tissue and cleft-subtype-specific variation
At identified CpGs, we used data from the Cleft Collective to explore whether methylation in blood was correlated
withmethylation at the site of the cleft (lip/palate), and whether meanmethylation varied according to cleft subtype
(CLO, CPO or CLP). One-way ANOVA was used to compare the mean methylation of subtypes, adjusting for
sex and surrogate variables designed to capture technical batch and cell composition effects.
Results
Testing for mediation: MR of the effect of methylation on liability to nsCL/P
To identify CpGs where methylation may mediate genetic liability to nsCL/P, we used two sampleMRwith mQTL
from the ALSPAC data as the exposure and liability to nsCL/P as the outcome (from the nsCL/P GWAS meta-
analysis summary statistics). We found evidence for an effect of methylation on liability to nsCL/P at 26 CpGs
after a multiple testing correction for the number of different CpGs tested (Bonferroni-corrected p-value < 0.05,
corresponding to an uncorrected p-value < 7.8 × 10-6). Of these 26 CpGs, 20 were instrumented by single
mQTL and six were instrumented by two mQTL each. When the six CpGs with two mQTL each were re-tested,
taking into account LD between the SNPs, only one (cg02598441 at LOC146880) survived correction for multiple
testing. These 21 mQTL were therefore taken forward to the reverse-causation step.
As a sensitivity analysis, we investigated all 21 of the ALSPAC mQTL in data from the GOYA cohort. 17 of the
21 CpG–SNP pairings passed quality control and were present in the GOYA data, of which 16 replicated in the
same direction with p < 0.05 (Supplementary Table 1).
Testing for reverse causation: MR of the effect of genetic liability to nsCL/P on methylation
Next, we tested if the association between the mQTL and liability to nsCL/P arose because genetic liability to
nsCL/P influences variation in methylation, by using two sample MR with genetic liability to nsCL/P as the
exposure and methylation as the outcome. We found no strong evidence that genetic liability to nsCL/P influences
variation in methylation at the 21 CpGs (Table 1). However, it should be noted that this step is very likely to be
limited by statistical power.
future science group www.futuremedicine.com 137
Research Article Howe, Richardson, Arathimos et al.
Table 1. Results of the forward (methylation→ nonsyndromic cleft lip with or without cleft palate) and reverse
(nonsyndromic cleft lip with or without cleft palate→ methylation) Mendelian randomization and the colocalization
analyses in Avon Longitudinal Study of Parents and Children.
SNP (allele 1/allele 2; annotated
gene)
CpG (annotated gene) Forward MR (effect size
[standard error]; p-value)
Reverse MR (effect size
[standard error]; p-value)
Colocalization (JLIM statistic;
p-value by permutation)
rs12057415 (T/C; n/a) cg09549015 (F3) -1.1 (0.2); 1.1 × 10-6 0.04 (0.07); 0.59 -8.5; 1
rs12057415 (T/C; n/a) cg26112574 (n/a) 0.7 (0.1); 1.1 × 10-6 0.00 (0.05); 1.00 -16.7; 1
rs861020 (A/G; IRF6) cg12766975 (IRF6) 1.1 (0.2); 1.1 × 10-6 0.00 (0.04); 0.99 -11.8; 1
rs861020 (A/G; IRF6) cg09163369 (C1orf107) -0.5 (0.1); 1.1 × 10-6 -0.04 (0.08); 0.59 -36.1; 1
rs861020 (A/G; IRF6) cg23166289 (C1orf107) -0.7 (0.2); 1.1 × 10-6 -0.01 (0.06); 0.92 -36.8; 1
rs861020 (A/G; IRF6) cg05527609 (C1orf107) 0.9 (0.2); 1.1 × 10-6 -0.06 (0.06); 0.31 -2.1; 0.69
rs4422741 (C/T; n/a) ch.8.2579072R (n/a) 0.7 (0.1); 2.1 × 10-10 0.11 (0.06); 0.08 -2.4; 0.91
rs4752028 (C/T; SHTN1) cg00750430 (SHTN1) 1.2 (0.2); 8.7 × 10-9 0.13 (0.11); 0.25 -16.7; 1
rs4752028 (C/T; SHTN1) cg03968911 (SHTN1) -0.8 (0.1); 8.7 × 10-9 -0.11 (0.19); 0.58 -32.2; 1
rs4752028 (C/T; SHTN1) cg11398452 (VAX1) -0.8 (0.1); 8.7 × 10-9 -0.11 (0.19); 0.56 30.2;  0.001
rs1258763 (C/T; n/a) cg04870120 (n/a) -1.2 (0.3); 1.3 × 10-6 0.04 (0.05); 0.38 -68.4; 1
rs1873147 (G/A; n/a) cg04194852 (TPM1) 1.5 (0.3); 1.5 × 10-8 0.09 (0.10); 0.38 -13.1; 1
rs8076457 (T/C; NTN1) cg18901140 (n/a) -1.1 (0.2); 3.0 × 10-7 0.02 (0.07); 0.74 -34.6; 1
rs8076457 (T/C; NTN1) cg19788727 (NTN1) -0.9 (0.2); 3.0 × 10-7 0.03 (0.05); 0.51 -13.9; 1
rs8076457 (T/C; NTN1) cg02481697 (NTN1) -0.8 (0.2); 3.0 × 10-7 0.01 (0.05); 0.83 0.65; 0.01
rs8076457 (T/C; NTN1) cg01862363 (NTN1) -0.6 (0.1); 3.0 × 10-7 0.03 (0.09); 0.78 0.11; 0.016
rs8076457 (T/C; NTN1) cg16107528 (NTN1) -0.7 (0.1); 3.0 × 10-7 -0.01 (0.05); 0.98 4.3;  0.001
rs1808191 (C/A; PLEKHM1P1) cg14501219 (LOC146880) -1.0 (0.2); 2.9 × 10-6 0.09 (0.05); 0.051 N/A†
rs1991401 (G/A; CEP95) cg02598441 (LOC146880) 0.4 (0.1); 4.3 × 10-7 -0.04 (0.07); 0.59 N/A‡
rs1808191 (C/A; PLEKHM1P1)
rs3746101 (T/G; MKNK2) cg05254098 (MKNK2) -1.0 (0.2); 5.0 × 10-6 -0.03 (0.05); 0.54 -37.2; 1
rs3746101 (T/G; MKNK2) cg17068236 (MKNK2) 0.8 (0.2); 5.0 × 10-6 -0.02 (0.05); 0.58 -91.0; 1
†This region was too sparsely genotyped to apply the colocalization analysis.
‡This CpG had two mQTL, so we did not apply the colocalization analysis.
JLIM: Joint likelihood mapping; MR: Mendelian randomization; mQTL: Methylation quantitative trait loci; SNP: Single nucleotide polymorphism.
Testing for linkage: joint-likelihood mapping to assess colocalization
We used JLIM, a colocalization method, to assess if there was evidence that methylation and liability to nsCL/P
are driven by the same causal effect at each locus. Of the 20 CpGs instrumented by one mQTL each, we found
evidence for colocalization at four CpGs (cg11398452, cg01862363, cg02481697 and cg16107528). With the
addition of the CpG site associated with two mQTL (cg02598441), we found strongest evidence that methylation
at five CpGs are putative mediators of genetic liability to nsCL/P at four different SNPs (Table 1).
Of these four SNPs, three were available and tested in the imputed GOYA data (rs807647, rs1808191 and
rs4752028). Two of the SNPs (intergenic rs8076457 and rs1808191 near PLEKHM1P1) consistently replicated as
mQTL in GOYA, with the third SNP rs4752028 replicating as an mQTL for two out of three CpG sites but not
the CpG–SNP pairing with evidence of colocalization (Supplementary Table 1).
Comparison between methylation & gene expression
To assess further evidence for a functional effect of our identified mQTL on gene expression, we performed a
look-up of the four identified SNPs in the GTex and NESDA NTR Conditional eQTL databases. We found
strong evidence that rs4752028 at SHTN1 is an eQTL for SHTN1 in whole blood (Table 2). There was also
strong evidence that both rs1808191 at PLEKHM1P1 and rs1991401 at CEP95/DDX5 are eQTL for six nearby
genes, including CEP95 (whole blood) and DDX5 (whole blood), which were identified through both databases
(Table 2). There was no available evidence in either catalogue that intergenic SNP rs8076457 is associated with
gene expression (Table 2).
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Table 2. Associations with gene expression at identified SNPs in two expression quantitative trait loci databases.
SNP (annotated gene) CpG (annotated gene) GTex: Gene, tissue, effect size, p-value NESDA NTR Conditional eQTL Catalog:
Gene, tissue, effect size, p-value
rs4752028 (SHTN1) cg11398452 (VAX1) SHTN1, whole blood, 0.35, 1.4 × 10-15 SHTN1, whole blood, 0.68, 2.7 × 10-159
rs8076457 (NTN1) cg01862363 (NTN1) N/A N/A
cg02481697 (NTN1)
cg16107528 (NTN1)
rs1808191 (PLEKHM1P1) cg02598441 (LOC146880) RP13-104F24.3, sun exposed skin, -0.31, 1.8
× 10-15
SMURF2, transformed fibroblasts, 0.28, 3.8
× 10-13
has-mir-6080, sun exposed skin, -0.29, 1.5 ×
10-11
PLEKHM1P, sun exposed skin, -0.13, 3.2 ×
10-5
N/A
rs1991401 (CEP95) DDX5, whole blood, -0.30, 1.8 × 10-19
CEP95, whole blood, 0.14, 2.3 × 10-7
MILR1, whole blood, 0.24, 1.4 × 10-5
DDX5, whole blood, -0.22, 6.2 × 10-108
CEP95, whole blood, 0.13, 1.3 × 10-16
eQTL: Expression quantitative trait loci; NESDA: Netherlands study of depression and anxiety; NTR: Netherlands twin register; SNP: Single nucleotide polymorphism.
Table 3. Comparison to methylation data in blood samples from children with an orofacial cleft.
SNP (annotated
gene)
CpG (annotated
gene)
Forward MR: Effect
size†[standard
error]; p-value)
methWAS nsCL/P
EWAS: Effect
size‡[standard
error]; p-value)
Correlation
between blood
and lip in the
Cleft Collective:
Correlation
coefficient (95%
C.I.)
Correlation between blood and
palate in the Cleft Collective:
Correlation coefficient (95% C.I.)
p-value for difference
in mean blood DNA
methylation between
CLO, CLP and CPO in
the Cleft Collective
rs4752028 (SHTN1) cg11398452
(VAX1)
-0.8 (0.1); 8.7 × 10-9 0.01 (0.05);
9.4 × 10-3
0.20 (-0.01, 0.41) 0.07 (-0.00, 0.14) 0.148
rs8076457 (NTN1) cg01862363
(NTN1)
-0.8 (0.2); 3.0 × 10-7 -0.030 (0.037);
2.1 × 10-1
-0.04 (-0.24,
0.16)
-0.02 (-0.26, 0.22) 0.828
cg02481697
(NTN1)
-0.6 (0.1); 3.0 × 10-7 -0.023 (0.024);
1.7 × 10-1
0.29 (0.09, 0.49) -0.06 (-0.35, 0.23) 0.286
cg16107528
(NTN1)
-0.7 (0.1); 3.0 × 10-7 -0.019 (0.016);
1.2 × 10-1
0.34 (0.14, 0.54) -0.11 (-0.37, 0.15) 0.646
rs1808191 (CEP95)
rs1991401
(PLEKHM1P1)
cg02598441
(LOC146880)
0.4 (0.1); 4.3 × 10-7 0.020 (0.007);
2.4 × 10-3
0.32 (0.12, 0.52) 0.13 (-0.15, 0.41) 0.548
rs1991401
(PLEKHM1P1)
†Effect size for forward MR can be interpreted as the difference in risk of nonsyndromic CL/P per standard deviation increase in methylation beta value.
‡Effect size for the methWAS EWAS can be interpreted as the difference in mean methylation beta value in participants with nonsyndromic CL/P compared with controls; MR:
Mendelian randomization.
CLO: Cleft lip only; CLP: Cleft lip with cleft palate CPO: Cleft palate only; CL/P: Cleft lip with or without cleft palate; EWAS: Epigenome-wide association study; SNP: Single nucleotide
polymorphism.
Comparison to EWAS results
To provide further evidence for an association between methylation and nsCL/P at our identified CpGs, we
compared the MR results (relating to liability to nsCL/P in the general population) to results from an nsCL/P
case–control EWAS study. At cg02598441 (LOC146880), the direction of effect estimated in our first (forward)
MR analysis was concordant with that in the EWAS study, with an EWAS p-value (2.4 × 10-3) that survived
Bonferroni correction for five tests (Table 3). The direction of estimated effect was also concordant between studies
at the three CpGs at NTN1, but the smallest EWAS p-value was 0.12. At cg11398452 (VAX1), the direction of
estimated effect was discordant between our MR analysis and the Brazilian EWAS, with a small EWAS p-value
(9.4 × 10-3; Table 3).
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Tissue & cleft-subtype-specific variation
We assessed correlations in methylation at our identified CpGs between different tissues (blood and lip/palate) and
cleft subtypes (CPO, CLP, CLO) to explore tissue- and subtype-specific variation. At most of the five identified
CpGs, there was evidence of weak correlation (correlation coefficients ranging -0.11 to 0.32) between methylation
in blood, lip and palate tissues, particularly between blood and lip tissue. We found weak evidence that mean
methylation values in any of the three tissues differed between cleft subtypes. However, the analysis was likely
underpowered to give precise correlation estimates (Table 3).
Discussion
In this study, we employed a framework that aims to identify putative mediators of genetic influences on nsCL/P
via DNAmethylation. We found five CpG sites, in three independent regions (VAX1, LOC146880, NTN1), where
bidirectional MR and colocalization analyses suggested that the same variant affects both methylation and nsCL/P
or where evidence was found that two independent variants affect both nsCL/P and methylation (Figure 1).
We found lower methylation at the CpG at VAX1 (cg11398452) in association with the nsCL/P risk allele C
of the SNP rs4752028 at SHTN1. This SNP is strongly associated with lower expression of SHTN1 according to
two eQTL databases. VAX1 is a homeobox containing gene that has been shown to be expressed in the developing
brain [46,47] and SNPs in VAX1 have been shown to be associated with nsCL/P in multiple independent GWAS
across distinct populations [4,8,9,48,49]. VAX1 knock-out mice have been shown to develop cleft palate, suggesting
VAX1 has a potentially important role in nsCL/P etiology [4]. SHTN1, sometimes known as KIAA1598, codes for
the protein shootin1 that is involved in neuronal polarization [50] and has also been reported to be relevant to the
etiology of nsCL/P in several studies [9,51,52]. It is difficult to distinguish the more significant locus between the
VAX1 and SHTN1 genes because of their close proximity and similar expression profiles in mice [9,47,52,53]. We did
not replicate the association between methylation at cg11398452 and rs4752028 in the GOYA data, but we did
find that the SNP was strongly associated with methylation at nearby probes. Similarly, the direction of association
between cg11398452 methylation and nsCL/P was the opposite in our MR study, compared with a previously
published observational EWAS [16].
We found higher methylation at the CpG at LOC146880 (cg02598441) in association with the G allele of
rs1991401 in DDX5 and the C allele of rs1808191 in PLEKHM1P. rs1991401 in DDX5 was associated with
reduced expression of DDX5 and increased expression of CEP95 andMILR1 while rs1808191 in PLEKHM1P was
associated with increased expression of SMURF2 but decreased expression of PLEKHM1P, RP13-104F24.3 and
has-mir-6080. However, there was weak evidence that the SNPs affected expression of the same genes. DDX5 is
involved in RNA helicase processes that are highly relevant to important cellular processes while PLEKHM1P and
LOC146880 are pseudogenes [47]. There is no robust evidence from previous literature to support an association
between genetic variation in these genes and nsCL/P. The SNP in PLEKHM1P replicated as an mQTL in the
GOYA dataset but there were insufficient data to test the SNP in DDX5.
We found lower methylation at three CpGs at NTN1 in association with the nsCL/P risk allele T of the
SNP rs8076457, an intergenic SNP close to NTN1. rs8076457, the mQTL for cg08162363, cg02481697 and
cg16107528, did not robustly associate with gene expression levels in two datasets. The function of NTN1 is
still largely unknown, but is thought to be involved in cell migration during development [47]. NTN1 has been
previously discussed as a strong candidate gene for nsCL/P [13]; NTN1 may affect liability to nsCL/P via epistatic
interactions, there is some evidence that NTN1 knock-out mice show consistency with the cleft palate phenotype
and NTN1 expression is localized to the palate [13,54]. rs8076457 replicated as an mQTL across all relevant CpGs
in the GOYA dataset.
Previous work has identified many functional possibilities for genetic risk variants for nsCL/P [15,54,55] but this
study adds to the current evidence for DNA methylation playing a role in the etiology of nsCL/P. Additional
strengths of this study include the integration of multiple data sources, for example ALSPAC, which provided
access to detailed phenotype, genotype and epigenetic data. The nsCL/P GWAS summary statistics allowed a
comprehensive genome-wide analysis in a large dataset. The Brazilian cohort EWAS results allowed a comparison
of the influence of methylation on nsCL/P according to observational and MR studies. The use of the GOYA
replication cohort, allowed triangulation of evidence for mQTL across different studies. Finally, the Cleft Collective
data allowed us to compare genome-wide DNA methylation in different tissues and subtypes of cleft.
There are, several limitations to this study. First, methylation and expression in the studied tissues (postnatal
cord blood, whole blood, lip and palate tissue) are unlikely to accurately reflect that in the developing orofacial
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tissue where epigenetic processes could feasibly influence susceptibility to nsCL/P. Since it is not possible to study
DNA methylation in the developing orofacial region of affected individuals, we explored correlations between
blood and lip/palate as a best available alternative. We found weak correlation between DNA methylation at our
putative causal regions in blood and lip/palate samples from individuals in the Cleft Collective. A previous study
found high blood-lip/palate correlation at CpGs identified as differentially methylated between nsCL/P cases and
controls [16]. Correlations in methylation signatures across tissues in the same individuals provide support for effects
that are not specific to certain tissues. For example, a recent study showed strong correlation of cis- eQTL and
mQTL effects between two tissues (brain and blood) [56]. However, without data on the relevant tissue, it remains
possible that the methylation and expression signatures of blood, lip and palate could be poorly representative of
those in the developing orofacial tissues. Second, CLO and CLP cases were analyzed together as one group in
the GWAS, MR analyses and the previously published EWAS. Increasingly, evidence suggests that these subtypes
are molecularly and etiologically distinct and should be analyzed separately [2,3], but we were limited by the data
available from previous studies. Although we found no evidence of differential methylation between subtypes at our
five identified CpGs, there may be other loci where methylation mediates genetic influences on more specific cleft
subtypes. Third, although efforts were made to select only nonsyndromic cases for the Cleft Collective analysis,
we cannot guarantee that no syndromic cases were included, and children with syndromes may have very different
methylation profiles. Fourth, a major limitation of this study is that some of the steps, particularly the reverse MR
(testing the effect of liability to nsCL/P on methylation), are likely to be statistically underpowered. Liability to
nsCL/P has been previously shown to have a causal affect on facial morphology [57] suggesting that it could also
affect methylation. Fifth, as the majority of mQTL were instrumented by just a single genetic variant, we were
unable to distinguish between mediation and horizontal pleiotropy and therefore proposed mediation is putative.
Finally, our comparisons with other cohorts may be affected by technical differences, tissue differences (cord blood
vs whole blood), ancestral differences between cohorts, age of participants (newborns vs children over 6 years old,
a lack of statistical power giving rise to spurious associations or the enrichment of GOYA for overweight and obese
mothers, which may introduce selection bias. Indeed, although mQTL were largely concordant between ALSPAC
and GOYA, the mQTL and CpG site (in SHTN1) found to colocalize with liability to nsCL/P in ALSPAC did not
replicate in GOYA. Similarly, the CpG site cg11398452, close to SHTN1, was directionally discordant between
our analyses and the results of a Brazilian EWAS.
Conclusion
We identified three putative loci where DNA methylation may mediate genetic susceptibility to nsCL/P with
stronger conclusions limited by the use of blood as a proxy for developing orofacial tissues. Future work determining
the function of these genes and the epigenetic modulation of their expression relevant to prenatal orofacial
development could provide important etiological insights. One possibility, warranting further investigation, is that
identified DNA methylation differences are related to environmental exposures.
Future perspective
Increase in the availability and size of integrated DNA methylation, gene expression and genotype datasets will
enable comprehensive evaluation of the role of epigenetic processes in disease etiology. In particular for congenital
traits like nsCL/P, the unavailability of the most ‘relevant’ embryonic tissue is always likely to be a limitation
for human studies. However, large-scale efforts to identify genetic variants that influence epigenetic processes
in a tissue-independent manner will be invaluable to MR studies that will help mitigate this concern. Relating
nsCL/P-associated epigenetic processes to environmental exposures that are risk factors for nsCL/P, may lead to
the development of targeted interventions.
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Summary points
• Nonsyndromic cleft lip with or without cleft palate (nsCL/P) is a complex trait with genetic and environmental
risk factors.
• Around 40 distinct genetic risk loci have been identified for nsCL/P, but many reside in nonprotein-coding regions
with an unclear function.
• We hypothesize that epigenetic processes may play an important role in the etiology of nsCL/P.
• To explore whether nsCL/P genetic risk variants influence liability to nsCL/P through gene regulation pathways
involving DNA methylation, we combined data from multiple sources and used an analysis framework involving
Mendelian randomization and joint likelihood mapping.
• We find putative evidence that genetic variation in VAX1, LOC146880 and NTN1 may increase liability to nsCL/P
via changes in DNA methylation.
• Methylation in blood, lip and palate tissue may not be strongly representative of that in the developing orofacial
tissues, which limits stronger conclusions.
• The study highlights the potential role for DNA methylation in the etiology of nsCL/P.
• Future work exploring the influence of prenatal environmental factors on DNA methylation related to nsCL/P is
warranted.
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